Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT04362839	TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2020-04-27	Location California, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy	Tags MSS/ MMRp
NCT ID NCT04110093	TitleRegorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer	Phase Phase 1/Phase 2	Date Added 2019-10-01	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Regorafenib and PD-1 inhibitor	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06006923	TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer	Phase Phase 2	Date Added 2023-08-23	Location California, United States Florida, United States Illinois, United States Pennsylvania, United States Washington, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Pembrolizumab, Regorafenib, Keytruda, Stivarga	Tags MSI-H/ MMRd
NCT ID NCT06456515	TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC	Phase Not Applicable	Date Added 2024-06-13	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT03657641	TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2018-09-05	Location California, United States Florida, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Pembrolizumab, Regorafenib, Keytruda, Stivarga	Tags MSS/ MMRp
NCT ID NCT04626635	TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors	Phase Phase 1, Phase 2	Date Added 2020-11-12	Location California, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States France Israel Netherlands Poland Spain Turkey	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs cemiplimab, REGN7075	Tags MSS/ MMRp
NCT ID NCT03388632	TitleRecombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers	Phase Phase 1	Date Added 2018-01-03	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05785325	TitleRC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer	Phase Phase 2	Date Added 2023-03-27	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs RC48-ADC plus Bevacizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05292417	TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC	Phase Phase 2	Date Added 2022-03-23	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Fruquintinib, GM-CSF, Sintilimab	Tags MSS/ MMRp
NCT ID NCT04050709	TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers	Phase Phase 1	Date Added 2019-08-08	Location California, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs PD-L1 t-haNK	Tags MSS/ MMRp

Showing 71 to 80 of 299 entries